NICE News

19 Jan 2023

NOTE TO MEDIA: Thursday, 19 January 2023. NICE recommends treatment for rare inherited liver condition

Although we will not be issuing a formal press release, we wanted to let you know that today (19 January 2023) NICE has issued final draft guidance which recommends vutrisiran (also called Amvuttra and made by Alnylam Pharmaceuticals) as an option for some adults with hereditary transthyretin-related amyloidosis (hATTR).

hATTR is estimated to affect around 150 people in the UK. It is a progressive condition that causes the liver to produce abnormal transthyretin protein. Deposits of transthyretin form in the tissues of the body (amyloidosis) and these can disrupt the structure and damage the function of the affected tissues.

Over time, these deposits can cause symptoms of polyneuropathy (such as pain, loss of sensation and weakness in the hands, arms, legs or feet) and symptoms of cardiomyopathy (such as chest pain, shortness of breath and fluid overload). In some cases, the autonomic nervous system which controls involuntary body functions such as blood pressure, heart rate, and digestion, may also be affected by amyloidosis.

The final draft guidance recommends vutrisiran as an option for people who have mild symptoms and can walk (stage 1 polyneuropathy) or who have moderate symptoms and require assistance to walk (stage 2 polyneuropathy).

NICE already recommends patisirian and inotersen as treatment options for stage 1 and stage 2 polyneuropathy.

Vutrisiran is an RNA interference (RNAi) therapeutic that inhibits the production of disease-causing transthyretin (TTR) protein by the liver, leading to a reduction in the level of TTR in the blood. It is administered by injection under the skin every 3 months.

Vutrisiran costs £95,862.36 per injection. At the recommended dose the estimated annual cost per patient is £383,449.44. The company has a confidential commercial that makes vutrisiran available to the NHS with a discount.

Vutrisiran is one of the first medicines to be recommended by NICE as part of its new proportionate approach to technology appraisals. This is designed to enable a flexible and pragmatic approach to appraisals and recognises that not all technologies need the full intensity of NICE’s existing appraisals process.

In this case the benefits and costs of vutrisiran were compared with those of patisiran. The analyses suggest that vutrisiran works as well as patisiran and, because it is administered every 3 months compared with patisiran’s administration by infusion every 3 weeks, it costs significantly less per patient.

By simplifying, removing, or reconfiguring parts of the appraisals process (for example, for this appraisal the technical engagement step was removed and the committee decision was taken outside of a formal meeting) NICE can produce final draft guidance faster. In this case the process was 20 weeks faster, or nearly 60%, than its standard appraisal process.  

The final draft guidance has been released for appeal to the company and registered stakeholders. If there are no appeals to NICE’s decision, final guidance is expected to be published in February 2023.

You can read the final draft guidance on vutrisiran for treating hereditary transthyretin-related amyloidosis on the NICE website.


Contact Information

Notes to editors

CSI_63c902e34a471cc35cc9d2ec

About NICE

NICE’s core purpose is to help practitioners and commissioners get the best care to people, fast, while ensuring value for the taxpayer.

We do this by:

  • producing useful and usable guidance for health and care practitioners
  • providing rigorous, independent assessment of complex evidence for new health technologies
  • developing recommendations that focus on what matters most and drive innovation into the hands of health and care practitioners
  • encouraging the uptake of best practice to improve outcomes for everyone.

To find out more about what we do, visit our website: www.nice.org.uk and follow us on social media.